US20210052734A1 - Peptide-mediated intravesical delivery of therapeutic and diagnostic agents - Google Patents
Peptide-mediated intravesical delivery of therapeutic and diagnostic agents Download PDFInfo
- Publication number
- US20210052734A1 US20210052734A1 US17/080,300 US202017080300A US2021052734A1 US 20210052734 A1 US20210052734 A1 US 20210052734A1 US 202017080300 A US202017080300 A US 202017080300A US 2021052734 A1 US2021052734 A1 US 2021052734A1
- Authority
- US
- United States
- Prior art keywords
- protamine
- bladder
- growth factor
- antisense oligonucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 48
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title description 18
- 229940124597 therapeutic agent Drugs 0.000 title description 8
- 239000000032 diagnostic agent Substances 0.000 title description 7
- 229940039227 diagnostic agent Drugs 0.000 title description 7
- 230000001404 mediated effect Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 23
- 210000003443 bladder cell Anatomy 0.000 claims abstract description 10
- 108010007568 Protamines Proteins 0.000 claims description 84
- 102000007327 Protamines Human genes 0.000 claims description 84
- 229940048914 protamine Drugs 0.000 claims description 61
- 108091034117 Oligonucleotide Proteins 0.000 claims description 40
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 37
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 37
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 23
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 23
- 229940053128 nerve growth factor Drugs 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 7
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 208000020629 overactive bladder Diseases 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 230000027939 micturition Effects 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 abstract description 41
- 239000000203 mixture Substances 0.000 abstract description 24
- 125000000129 anionic group Chemical group 0.000 abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 78
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 78
- 210000003932 urinary bladder Anatomy 0.000 description 59
- 108020004707 nucleic acids Proteins 0.000 description 42
- 102000039446 nucleic acids Human genes 0.000 description 42
- 150000007523 nucleic acids Chemical class 0.000 description 42
- 230000000670 limiting effect Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 229950008679 protamine sulfate Drugs 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000000692 anti-sense effect Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 8
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 8
- 108090000099 Neurotrophin-4 Proteins 0.000 description 8
- 102100033857 Neurotrophin-4 Human genes 0.000 description 8
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 8
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 8
- 230000004700 cellular uptake Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 108020004459 Small interfering RNA Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 4
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 4
- 102000004072 Beclin-1 Human genes 0.000 description 4
- 108090000524 Beclin-1 Proteins 0.000 description 4
- 102100035904 Caspase-1 Human genes 0.000 description 4
- 108090000426 Caspase-1 Proteins 0.000 description 4
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 4
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000831940 Homo sapiens Stathmin Proteins 0.000 description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 description 4
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 4
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 4
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 4
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 4
- 102000003683 Neurotrophin-4 Human genes 0.000 description 4
- 241000277329 Oncorhynchus keta Species 0.000 description 4
- 101100520074 Oryza sativa subsp. japonica PIK-1 gene Proteins 0.000 description 4
- 102000005465 Stathmin Human genes 0.000 description 4
- 108050003387 Stathmin Proteins 0.000 description 4
- 102100024237 Stathmin Human genes 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- -1 cationic lipid Chemical class 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 229940097998 neurotrophin 4 Drugs 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 4
- 210000003741 urothelium Anatomy 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000036724 intravesical pressure Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710150620 Anionic peptide Proteins 0.000 description 1
- 101710120040 Antifungal peptide Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010056948 Automatic bladder Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 101100408379 Drosophila melanogaster piwi gene Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Chemical group 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 241000276569 Oryzias latipes Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710168705 Protamine-1 Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101100404655 Rattus norvegicus Ngf gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 102100040435 Sperm protamine P1 Human genes 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 101100514842 Xenopus laevis mtus1 gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000014537 nerve growth factor production Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Definitions
- the present invention relates to methods and compositions for administering agents to cells in the bladder, whereby a cationic peptide or a mixture of cationic peptides is used to deliver an anionic therapeutic or diagnostic agent.
- ODN anti sense oligonucleotide
- Cationic lipids have been used in the past to deliver ODN [7, 8], but that method requires organic solvents and expert handling for formulating the ODN and lipid together prior to use.
- the binding between the negatively charged DNA phosphate groups and the cationic lipid [8] or peptide carrier is achieved by ionic interaction.
- Traditional approaches using cationic peptides or polysaccharides [9] require covalent binding between the vector and the drug.
- Covalent binding to cationic peptide polylysine requires elaborate application of chemistry tools [10, 11].
- Phosphorothioate-modified ODN [12] are lipophilic and have increased stability against nucleolytic degradation [13].
- compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells.
- a composition comprises an anionic drug or antisense oligonucleotide and a mixture of cationic peptides comprising protamine, and is used for intravesical drug delivery.
- the cationic peptide(s) acts as a carrier through non-covalent association with the anionic agent and facilitates delivery of the agent into bladder cells.
- FIG. 1A-G (A-F) Cellular uptake studies of ODN: UROtsa cells were incubated for 4 h at 37° C. with (A) naked 5′-TYETM 563 labelled Phosphorothioate oligonucleotide (ODN), (B) 1:1 (C) 1:5 ODN/protamine particles. Cells were washed at the end of 4 h exposure to ODN mixture and the fluorescent images were captured following further incubation of treated cells for 24 hours at 37° C. The bright red fluorescence demonstrates successful uptake and retention of ODN. Respective bright field images are shown below in panels D, E and F.
- FIG. 2A-I Cellular uptake studies of ODN: Uptake of fluorescent oligonucleotide by uroepithelium cells in culture at higher protamine: oligonucleotide ratios.
- UROtsa cells were incubated for 4 h at 37° C. with (A) 5′-TYETM 563 labelled Phosphorothioate oligonucleotide and protamine in 1:10, (B) 1:20 (C) 1:40 ODN/protamine particles. Cells were washed at the end of 4 h exposure to ODN mixture and the fluorescent images were captured following further incubation of treated cells for 24 hours at 37° C. Respective bright field images are shown in panels, D, E and F.
- the amount of fluorescent oligonucleotide added to each well was always and the protamine amount varied from 10, 20 and 40 ⁇ g in panels A, B and C, respectively.
- Exposure time was constant in all images at 1.2 sec in panels A, B and C with magnification 10 ⁇ and corresponding images at higher magnification for each panel are shown in panels G, H and I.
- FIG. 3A-D Bladder Uptake of ODN: Results of in vivo instillation of fluorescent oligonucleotide and protamine sulfate into rat bladder, showing fluorescence 24 hours later. Fluorescence images of rat bladders harvested 24 h post-instillation with antisense oligonucleotide with 5′ tag of TYETM 563 at 15 ⁇ g/mL complexed with 150 ⁇ g/mL protamine sulfate (panel A) and those instilled with ODN 30 ⁇ g/mL complexed with 300 ⁇ g/mL of protamine sulfate (panel B).
- the bright red fluorescence demonstrates successful uptake and retention in target cells of ODN delivered by protamine and higher concentration of ODN led to deeper penetration of ODN into the bladder (panel B). Fluorescence integrated intensity images are shown in respective sections to confirm the source of red fluorescent signal. Lumen side of the section is marked by a white arrow. Magnification is 10 ⁇ in all sections.
- FIG. 4 Functional Effect of ODN Carried By Protamine: Cystometric analysis of bladder overactivity in treated groups induced by intravesical application of acetic acid (“AA”; 0.25%). Top tracing: Representative CMG was performed 24 h post-instillation of 0.3 mg/mL protamine (sham group), binary complex of antisense ODN (15 ⁇ g) and protamine (middle trace) and antisense ODN (30 ⁇ g) complexed with protamine (bottom trace). Baseline CMG (60 min prior to acetic acid infusion) and post-acetic acid cystometry are shown in left and right traces, respectively.
- the present invention relates to methods and compositions for administering agents to cells in the bladder, whereby a cationic peptide or mixture of cationic peptides is used to deliver one or more anionic therapeutic or diagnostic agents.
- a cell in the bladder may be any cell located in the bladder, including, but not limited to, a urothelial cell (which also may be referred to as a “uroepithelial cell”) which may be an umbrella, intermediate, or basal cell, a muscle cell, a fibroblast, an endothelial cell or a cancerous bladder cell, for example a urothelial carcinoma cell.
- a urothelial cell which also may be referred to as a “uroepithelial cell”
- a urothelial cell which may be an umbrella, intermediate, or basal cell, a muscle cell, a fibroblast, an endothelial cell or a cancerous bladder cell, for example a urothelial carcinoma cell.
- a “cationic peptide” is a peptide that has a net positive charge.
- the peptide is at least about 15 amino acids long, or at least about 20 amino acids long, or at least about 25 amino acids long, or at least about 30 amino acids long, and/or up to about 40 amino acids long, up to about 50 amino acids long, up to about 60 amino acids long, up to about 70 amino acids long, or between about 15 and 70 amino acids long, or between about 20 and 60 amino acids long, or between about 20 and 50 amino acids long.
- the cationic peptide comprises at least 30 percent or at least 50 percent positively or potentially positively charged amino acid residues selected from the group consisting of arginine, lysine, histidine, or mixtures thereof. In certain non-limiting embodiments, the cationic peptide comprises at least 30 percent or at least 50 percent arginine residues (relative to total number of amino acid residues). In certain non-limiting embodiments a cationic peptide according to the invention may comprise, alone or in combination, where the single letter code for amino acids is used:
- PRRRRRSSSR PIRRRRRPRAS RRRRRGGRRR R chlorum salmon peak A peptide; SEQ ID NO:4; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990);
- PRRRRSSRRP VRRRRRPRVSR RRRRGGRRRR chum salmon peak B peptide; SEQ ID NO:5; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990);
- PRRRRSSSRP VRRRRRPRVSR RRRRGGRRRR chum salmon peak C peptide; SEQ ID NO:6; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990); PRRRRASRRI RRRRRPRVSR RRRRGGRRRR (chum salmon peak D peptide; SEQ ID NO:7; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990); or
- a peptide comprising the sequence RRRX 1 X 2 RRR where X 1 or X 2 or both is/are G or V or A (SEQ ID NO:8).
- a single species of cationic peptide is used for delivery in the delivery formulation.
- a mixture of cationic peptides is used.
- a mixture of cationic peptides commercially available as protamine sulfate is used.
- the protamine sulfate may be as approved by the United States Food and Drug Administration, for example, as provided in a 10 mg/mL solution by Fresenius Kabi U.S.A. or an equivalent product.
- the cationic peptide may be linked to another peptide that does not qualify as a cationic peptide and/or to a non-amino acid or non-peptide component, such as, but not limited to, a lipid, a fatty acid, a carbohydrate or a nucleic acid.
- the cationic peptide may be conjugated to one or more additional molecule, for example, but not limited to, a carbohydrate, an antibiotic, an antiproliferative agent, a pharmaceutical, or another peptide, whose physiochemical properties makes them impermeable across urothelium.
- anionic agent is an agent that may be used as a diagnostic or therapeutic wherein at least a portion of the agent has a negative charge that can form a non-covalent attachment with a cationic peptide.
- the anionic agent is an antisense oligonucleotide.
- the antisense oligonucleotide is at least about 10 nucleic acids long, or at least about 15 nucleic acids long, or at least about 20 nucleic acids long, or at least about 25 nucleic acids long, or up to about 30 nucleic acids long, or up to about 50 nucleic acids long, or up to about 75 nucleic acids long, or up to about 100 nucleic acids long, or between about 15 and 75 nucleic acids long, or between about 15 and 40 nucleic acids long.
- the antisense oligonucleotide inhibits the expression/reduces the level of nerve growth factor.
- said nerve growth factor is human nerve growth factor encoded by a mRNA having a corresponding cDNA sequence set forth in GenBank Accession No. GenBank: M57399.1, as follows:
- analogous antisense oligonucleotides may be directed to mRNAs encoding Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF- ⁇ 1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/stathmin 1 or PIK-1, inflammatory proteins, cytokines, chemokines, caspase-1, or proteins involved in autophagy such as microtubule-associated protein 1 light chain 3 (LC3B), autophagy protein 5 ATGS, beclin 1, LAMP-2, for example but not limited to human Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF- ⁇ 1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/stathmin 1 or PI
- VEGF
- the anionic agent is an interfering RNA (siRNA) oligonucleotide.
- siRNA interfering RNA
- the siRNA oligonucleotide is at least about 10 nucleic acids long, or at least about 15 nucleic acids long, or at least about 20 nucleic acids long, or at least about 25 nucleic acids long, or up to about 30 nucleic acids long, or up to about 50 nucleic acids long, or up to about 75 nucleic acids long, or up to about 100 nucleic acids long, or between about 15 and 75 nucleic acids long, or between about 15 and 40 nucleic acids long.
- the siRNA oligonucleotide inhibits the expression/reduces the level of nerve growth factor.
- said nerve growth factor is human nerve growth factor encoded by a mRNA having the corresponding cDNA sequence set forth in GenBank Accession No.
- siRNA oligonucleotide is homologous to a portion thereof which is at least about 10 nucleic acids long, or at least about 15 nucleic acids long, or at least about 20 nucleic acids long, or at least about 25 nucleic acids long, or up to about 30 nucleic acids long, or up to about 50 nucleic acids long, or up to about 75 nucleic acids long, or up to about 100 nucleic acids long, or between about 15 and 75 nucleic acids long, or between about 15 and 40 nucleic acids long.
- analogous siRNA oligonucleotides may be directed to mRNAs encoding Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF- ⁇ 1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/stathmin 1 or PIK-1, inflammatory proteins, cytokines, chemokines, caspase-1, or proteins involved in autophagy such as microtubule-associated protein 1 light chain 3 (LC3B), autophagy protein 5 ATGS, beclin 1, LAMP-2, for example but not limited to human Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF- ⁇ 1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/stathmin 1 or PIK
- VEGF
- Such antisense or siRNA oligonucleotides may comprise non-naturally occurring bases or linkages as are known in the art, for example, but not limited to, phosphorothioate residues, 2′-O-methyl (2′-O-Me) phosphorothioate, 2′-O-methoxyethyl (2′-O-MOE) phosphorothioate residues, Oligodeoxyribonucleotides with phosphonoacetate or thiophosphonoacetate internucleotide linkages, locked nucleic acids, and/or synthethic microRNA, short hairpin RNA, small interfering RNA, piwi-associated RNAs negatively charged homo-oligomers of alternating trans-4-hydroxy-L-proline/phosphonate polyamides (HypNA-pPNA).
- anionic compounds that may be used as therapeutic or diagnostic agents include Bacille Calmette-Guerin cell wall skeleton, suramin and (polysulfonated naphtylurea), plasmid DNA, anionic peptides, anionic antifungal peptides.
- the invention provides for a pharmaceutical composition comprising said cationic peptide(s) and anionic agent(s) for intravesical administration to a subject (a delivery formulation).
- Said composition may be available as such or may be prepared shortly before administering to the subject by mixing the cationic peptide(s) with the anionic agent(s) or by reconstituting a mixture of the two.
- the cationic peptide mixture is a commercially available protamine injection solution which is mixed with the anionic agent prior to administering to the subject.
- the cationic peptide(s) and the anionic agent are provided as separate components in a kit, to be mixed together to form a delivery formulation shortly before administering to a subject.
- “Shortly before” means within about 30 days prior to use or within about one week prior to use or within about 3 days prior to use or within about 2 days prior to use or within about 24 hours prior to use or within about 12 hours prior to use or within about 8 hours prior to use.
- the present invention provides for a mixture that may comprise a therapeutic or diagnostic oligonucleotide in the concentration range of 2-20 micromolar mixed with cationic peptide or cationic peptide mixture (eg protamine sulfate) in the 20-200 micromolar range.
- a therapeutic or diagnostic oligonucleotide in the concentration range of 2-20 micromolar mixed with cationic peptide or cationic peptide mixture (eg protamine sulfate) in the 20-200 micromolar range.
- the cationic peptide is protamine and the concentration of protamine is less than 10 mg/mL, or less than 1 mg/mL, or less than 0.6 mg/mL, or less than 0.4 mg/mL, or between 0.2 mg/mL and 0.6 mg/mL, or between about 0.2 mg/mL and 0.4 mg/mL, or about 0.3 mg/mL, or about 0.4 mg/mL.
- the weight ratio of cationic peptide(s) to anionic agent is between about 1:1 to about 40:1 or between about 5:1 to about 30:1 or between about 5:1 to about 15:1 and/or may be about 1:1 or about 5:1 or about 10:1 or about 15:1 or about 20:1 or about 30:1 or about 40:1.
- the weight ratio of protamine sulfate to oligonucleotide is between about 1:1 to about 40:1 or between about 5:1 to about 30:1 or between about 5:1 to about 15:1 and/or may be about 1:1 or about 5:1 or about 10:1 or about 15:1 or about 20:1 or about 30:1 or about 40:1.
- compositions of the invention may further comprise one or more pharmaceutically suitable solvent, such as but not limited to water and/or saline, and may optionally comprise one or more additional therapeutic or diagnostic agent.
- pharmaceutically suitable solvent such as but not limited to water and/or saline
- the present invention provides for a method of treating a subject, in need of such treatment, with an anionic therapeutic agent, comprising administering into the bladder of the subject an effective amount of an anionic therapeutic agent in combination with a cationic peptide(s) in an amount that promotes the uptake of the therapeutic agent into bladder cells.
- the subject may be suffering from overactive bladder (“OAB”), bladder cancer, or interstitial cystitis.
- the present invention provides for a method of performing a diagnostic procedure on the bladder of a subject, comprising administering into the bladder of the subject an effective amount of an anionic diagnostic agent in combination with a cationic peptide(s) in an amount that promotes the uptake of the diagnostic agent into bladder cells, thereby enabling the diagnostic procedure.
- the diagnostic procedure may be an imaging procedure and the anionic agent may be an imaging dye, whereby the method enhances the ability of the dye to produce an image of the urothelium.
- the present invention provides for a method of treating a subject with overactive bladder, comprising administering into the bladder of the subject a therapeutic amount of an antisense oligonucleotide toward nerve growth factor in combination with a cationic peptide(s) in an amount that promotes the uptake of the antisense oligonucleotide into bladder cells to reduce the level of nerve growth factor and reduce the frequency of urination and/or feeling of urgency to urinate.
- the cationic peptide(s) is a mixture of cationic peptides as comprised in a protamine solution.
- a subject may be a human or a non-human subject, including but not limited to a non-human primate, a rodent, a rabbit, a dog, a cat, a horse, a goat, a cow or bull, a sheep, or a bird.
- Protamine which has been used as a component in the delivery system for gene and ODN in the past, but not in this context [14].
- Protamine is highly stable, well characterized and is used clinically as an antidote to heparin overdoses and a complexing agent for insulin in long-acting preparations [15]. It has, however, been reported to have toxic effects when instilled into bladder at relatively higher concentration [21-23].
- Oligonucleotides The 18mer phosphorothioated antisense oligonucleotide (ODN) was used in all experiments with the sequence 5′GCCCGAGACGCCTCCCGA (SEQ ID NO: 10), which was directed against unique sequence in exon 3 of rat NGF mRNA and was custom made by Integrated DNA technologies (San Diego, Calif.). ODN had a 5′ tag of TYETM 563 for uptake studies. Stock solution of HPLC grade ODN was prepared at 2 mM in nuclease free distilled water (Invitrogen, Grand Island, N.Y., USA).
- Protamine sulfate Grade X was purchased from Sigma (Catalog P4020) with a molecular mass of approx. 5.1 KDa and stock solution was prepared at 5 mg/mL. Aliquots of ODN solution containing 5 ⁇ g/mL were mixed in mass ratios ranging from 1:1 to 1:40 with aqueous solutions of Protamine sulfate 5-200 ⁇ g/mL. The binary complex was incubated at room temperature for 30 minutes prior to experiments and prepared fresh before every experiment.
- UROtsa cell line was maintained in a humidified incubator containing 5% CO2-95% atmospheric air at 37° C. in Minimum Essential Medium (Thermo Fisher Scientific, Pittsburgh, Pa.) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) antibiotic/antimycotic (Catalog Number 15240, Invitrogen).
- Intracellular uptake of TYETM-labeled ODN-10,000 cells of UROtsa cell line were plated in an eight-well tissue culture chamber slides made of glass (Falcon, Becton Dickinson, N.Y.) at 37° C. and after 19 h, plated cells were treated with 5 ⁇ g/mL of TYETM 563-labeled ODN or the binary complex containing ODN complexed with protamine 5-200 ⁇ g/mL in different mass ratios. All preparations were diluted 2-fold with incomplete media and incubated for 4 hours. After 4 hours, cells were washed to remove residual ODN preparations and then incubated with complete media for 19 h.
- Bladder uptake studies Rats were anesthetized with 2% isoflurane and their bladders were catheterized by 24-gauge angiocatheters (Becton Dickinson), washed with saline to instill 0.5 mL of fluorescent TYETM conjugated ODN dissolved in nuclease free water or complexed with protamine for 60 min. Rats restarted their voiding in metabolic cages at the end of instillation. Bladders were harvested at the time of sacrifice and cryopreserved for cryosectioning into 8 micron thick tissue sections. Sections were examined for fluorescence signal by fluorescence microscope equipped with a laser.
- a control CMG was performed by slowly filling the bladder with saline (0.04 mL/min) to elicit repetitive voiding for more than for 1 hour. Subsequently, bladder irritation was induced by 0.25% AA infusion. The ICI of the reflex bladder contractions during saline and AA was determined as the time between 2 continuing contraction cycles. The average of at least 3 ICIs measured for more than 30 min after saline infusion and 60 min after AA infusion, respectively was compared.
- the secondary donkey anti-rabbit Alexa Fluor 488 (1:200) (Molecular Probes, Eugene, Oreg.) antibody was applied for 2 h at room temperature in PBS containing 0.1% BSA, 0.1% Triton X-100. Washing was performed 3 ⁇ at room temperature in PBS, and sections were mounted with an aqueous mounting medium. Immunostaining was analyzed with a Nikon confocal microscope.
- NGF levels in harvested bladders The rat bladders were harvested at the end of cystometry. Tissues were homogenized in RIPA lysis buffer system (Santa Cruz Biotechnology Inc., USA) in the presence of 1 mM Na 3 VO 4 , 2 mM PMSF and 10 ⁇ L/mL protease inhibitor cocktail. Protein was estimated using pierce BCA protein Assay kit (Thermo Scientific, USA). Tissue lysates were stored at ⁇ 20° C. until assay and assayed in triplicate in an antigen capture ELISA Emax Immuno-Assay System (Promega, Madison, Wis.) according to the manufacturer's instructions.
- Tissue NGF values were normalized against the protein concentrations of each sample and expressed as picograms per milligram of protein.
- FIG. 2G-I Images taken at higher magnification demonstrate that protamine nanoparticles formed with ODN were localized in the nucleus ( FIG. 2G-I ).
- the binary complex showed toxicity at higher concentration of protamine sulfate in FIG. 1 bottom panel as revealed by decrease in cell viability relative to control untreated cells represented by 0 ⁇ g on x-axis. Higher concentration of protamine reduced cell viability.
- Protamine sulfate induced toxicity is also related to reduced fluorescence ( FIGS. 2C & F). Although cellular uptake and subcellular localization of fluorescent ODN is visible at higher magnification ( FIG. 2G-I ), images taken at lower magnification showed the uniform uptake of binary complexes and were better in revealing toxicity from higher concentrations of protamine, for example 40 ⁇ g per well or 0.2 mg/mL.
- Bladder Uptake Rat bladders harvested after ODN instillation were cryosectioned for viewing the red fluorescence under the microscope ( FIG. 3 ) The fluorescent signal was used as a measure of bladder uptake of ODN after instillation. Protamine mediated bladder uptake of ODN was evident from intense fluorescence of TYETM 563 in bladder sections. Increasing the dose of TYETM 563 labeled ODN, while keeping the mass ratio of ODN:protamine 1:10, increased the intensity of fluorescence in bladder. Our previous studies have demonstrated the naked ODN at the concentration of 15 ⁇ g/mL (or 0.015 mg/mL) does not transfer into the bladder cells[7]. Fluorescence integrated intensity images are shown below the fluorescent images to reveal the localization of fluorescent signal.
- Bladder NGF levels elevated the NGF production in the sham group relative to the control group. Pretreatment with NGF antisense ODN significantly blocked the AA induced NGF overexpression in the tissue lysates of bladder ( FIG. 5 ). Results of FIG. 5 can be directly inferred from the bladder uptake of ODN facilitated by protamine. NGF levels in control rat group not exposed to AA were not raised.
- a carrier for therapeutic oligonucleotides that is easy to make and instill in the bladder for in vivo experiments as described here has translation potential for patients that are refractory to traditional treatment of overactive bladder (“OAB”), bladder cancer or interstitial cystitis.
- Protamine is a natural and arginine-rich polycationic peptide of ⁇ 5.1 KDa. It is found in male gametes, where it forms compact structures with DNA and facilitates DNA delivery to the egg nucleus after fertilization. Protamine possesses several amino acid sequences resembling that of a nuclear localization signal[14], which may facilitate DNA delivery to nucleus. It is non-antigenic[16], due to the lack of aromatic amino acids and the lack of a rigid structure[17]. We hypothesized that cationic protamine can self-assemble with the anionic ODN, forming a stable complex, which facilitates the bladder uptake of ODN.
- Bladder instillation of antisense ODN can be an efficient means to control the expression of therapeutically relevant genes and elucidate the functional role of newly discovered genes in bladder function.
- Nerve growth factor has emerged as an attractive drug target for OAB [31] and its downregulation with antisense ODN is an potential approach [7].
- Recently cationic liposomes have been demonstrated to be effective in intravesical delivery of ODN [7].
- cationic liposomes will require further modification to curb their cytotoxicity [32] in the event that cystoscope-guided intradetrusor injection into bladder is considered for prolonged duration of action and in treatment of refractory patients.
- Protamine sulfate in the concentrations of about 0.3 mg/mL used here is less cytotoxic than cationic lipids used in liposomal formulation (7 mg/mL) for intradetrusor injection.
- Protamine is an effective carrier for delivering therapeutic ODN to bladder. It non-covalently binds to form a liquid complex for easy instillation into bladder.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biochemistry (AREA)
Abstract
Description
- This application is a continuation of United States patent application No. division of U.S. patent application Ser. No. 16/011,378, filed Jun. 18, 2018, which is a divisional application of U.S. patent application Ser. No. 14/846,536, filed Sep. 4, 2015, now U.S. Pat. No. 10,029,012, which claims priority to U.S. Provisional Application No. 62/046,585 filed Sep. 5, 2014, the contents of which are hereby incorporated by reference in their entireties herein.
- This invention was made with government support under Grant No. DK088836 awarded by the National Institutes of Health. The government has certain rights in the invention.
- The present invention relates to methods and compositions for administering agents to cells in the bladder, whereby a cationic peptide or a mixture of cationic peptides is used to deliver an anionic therapeutic or diagnostic agent.
- Introduction of short strands of antisense DNA with sequences complementary to the mRNA encoding a particular protein inside the cell is being explored as a therapeutic approach[1]. The inserted anti sense oligonucleotide (“ODN”) binds specifically and strongly to its mRNA target through Watson-Crick base pairing and blocks gene expression either through translational inhibition or enzymatic cleavage of the mRNA target [2]. Antisense therapeutics have been under clinical investigation for more than 30 years [3] for several diseases [4].
- Considering the anatomical architecture of bladder, the therapeutic principle for intravesical instillation of ODN is very appealing as it provides ease of local administration with restricted systemic side effects due to limited serum uptake of antisense ODN. However, applied research for bladder diseases has lagged behind other disciplines. Drug development of this approach has been hampered by inefficient cellular uptake of the ODN. Bladder uptake of naked ODN is generally poor, but is improved in presence of bladder cancer, when very high concentration of naked ODN [5] is instilled. It is known that tight junctions in urothelium are compromised in cancerous condition [6] and therefore the strategy of relying on concentration gradient may not work in non-cancerous diseased condition where the barrier is intact, such as in overactive bladder.
- Several approaches have been tried to increase the bladder uptake of ODN without compromising the bladder barrier, but all have limitations. Cationic lipids have been used in the past to deliver ODN [7, 8], but that method requires organic solvents and expert handling for formulating the ODN and lipid together prior to use. The binding between the negatively charged DNA phosphate groups and the cationic lipid [8] or peptide carrier is achieved by ionic interaction. Traditional approaches using cationic peptides or polysaccharides [9] require covalent binding between the vector and the drug. Covalent binding to cationic peptide polylysine requires elaborate application of chemistry tools [10, 11].
- The translation of basic antisense research into therapeutics is also impeded by intracellular stability of ODN and potential for “off-target” gene silencing, immunostimulation, and other side effects. Phosphorothioate-modified ODN [12] are lipophilic and have increased stability against nucleolytic degradation [13].
- A significant limitation for medicine, particularly treatments given by the intravesical route (via a catheter into the bladder), is the poor permeability of the bladder to outside agents. Efficient cellular uptake of many chemical agents is still a challenge.
- The present invention relates to compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells. In particular non-limiting embodiments, a composition comprises an anionic drug or antisense oligonucleotide and a mixture of cationic peptides comprising protamine, and is used for intravesical drug delivery. Without being bound to any particular theory, it is believed that the cationic peptide(s) acts as a carrier through non-covalent association with the anionic agent and facilitates delivery of the agent into bladder cells.
-
FIG. 1A-G . (A-F) Cellular uptake studies of ODN: UROtsa cells were incubated for 4 h at 37° C. with (A) naked 5′-TYE™ 563 labelled Phosphorothioate oligonucleotide (ODN), (B) 1:1 (C) 1:5 ODN/protamine particles. Cells were washed at the end of 4 h exposure to ODN mixture and the fluorescent images were captured following further incubation of treated cells for 24 hours at 37° C. The bright red fluorescence demonstrates successful uptake and retention of ODN. Respective bright field images are shown below in panels D, E and F. The amount of fluorescent oligonucleotide added to each well was always 1 μg and the protamine amount varied from 0, 1 and 5 μg in panels A, B and C, respectively. Exposure time in panel A with naked ODN was 5 sec and it was 1.2 sec in other panels at 10× magnification. (G) Effect of increasing protamine concentrations on viability of UROtsa cells is shown. -
FIG. 2A-I : Cellular uptake studies of ODN: Uptake of fluorescent oligonucleotide by uroepithelium cells in culture at higher protamine: oligonucleotide ratios. UROtsa cells were incubated for 4 h at 37° C. with (A) 5′-TYE™ 563 labelled Phosphorothioate oligonucleotide and protamine in 1:10, (B) 1:20 (C) 1:40 ODN/protamine particles. Cells were washed at the end of 4 h exposure to ODN mixture and the fluorescent images were captured following further incubation of treated cells for 24 hours at 37° C. Respective bright field images are shown in panels, D, E and F. The amount of fluorescent oligonucleotide added to each well was always and the protamine amount varied from 10, 20 and 40 μg in panels A, B and C, respectively. Exposure time was constant in all images at 1.2 sec in panels A, B and C with magnification 10× and corresponding images at higher magnification for each panel are shown in panels G, H and I. -
FIG. 3A-D : Bladder Uptake of ODN: Results of in vivo instillation of fluorescent oligonucleotide and protamine sulfate into rat bladder, showing fluorescence 24 hours later. Fluorescence images of rat bladders harvested 24 h post-instillation with antisense oligonucleotide with 5′ tag of TYE™ 563 at 15 μg/mL complexed with 150 μg/mL protamine sulfate (panel A) and those instilled with ODN 30 μg/mL complexed with 300 μg/mL of protamine sulfate (panel B). The bright red fluorescence demonstrates successful uptake and retention in target cells of ODN delivered by protamine and higher concentration of ODN led to deeper penetration of ODN into the bladder (panel B). Fluorescence integrated intensity images are shown in respective sections to confirm the source of red fluorescent signal. Lumen side of the section is marked by a white arrow. Magnification is 10× in all sections. -
FIG. 4 : Functional Effect of ODN Carried By Protamine: Cystometric analysis of bladder overactivity in treated groups induced by intravesical application of acetic acid (“AA”; 0.25%). Top tracing: Representative CMG was performed 24 h post-instillation of 0.3 mg/mL protamine (sham group), binary complex of antisense ODN (15 μg) and protamine (middle trace) and antisense ODN (30 μg) complexed with protamine (bottom trace). Baseline CMG (60 min prior to acetic acid infusion) and post-acetic acid cystometry are shown in left and right traces, respectively. Note that the AA-induced reduction in ICI was seen in a rat not treated with ODN (top tracing), but not in the group treated with NGF antisense complex with protamine to demonstrate the protective effect of antisense ODN. CMG parameters in absence of AA were not significantly different between groups. -
FIG. 5 : Effect on Bladder NGF levels: Bladder tissue harvested from each group was analyzed for NGF levels measured by ELISA (n=4). Exposure to acetic acid (“AA”) raised the NGF levels in sham group compared to control group that was not exposed to AA. Pretreatment with NGF antisense complexed with protamine (30 μg/mL) blunted the AA induced rise in NGF levels. ANOVA followed by Tukey's test showed significant reduction of NGF expression in rat group treated with NGF antisense (30 μg/mL) (*P<0.05) - The present invention relates to methods and compositions for administering agents to cells in the bladder, whereby a cationic peptide or mixture of cationic peptides is used to deliver one or more anionic therapeutic or diagnostic agents.
- A cell in the bladder may be any cell located in the bladder, including, but not limited to, a urothelial cell (which also may be referred to as a “uroepithelial cell”) which may be an umbrella, intermediate, or basal cell, a muscle cell, a fibroblast, an endothelial cell or a cancerous bladder cell, for example a urothelial carcinoma cell.
- A “cationic peptide” is a peptide that has a net positive charge. In certain non-limiting embodiments the peptide is at least about 15 amino acids long, or at least about 20 amino acids long, or at least about 25 amino acids long, or at least about 30 amino acids long, and/or up to about 40 amino acids long, up to about 50 amino acids long, up to about 60 amino acids long, up to about 70 amino acids long, or between about 15 and 70 amino acids long, or between about 20 and 60 amino acids long, or between about 20 and 50 amino acids long. In certain non-limiting embodiments, the cationic peptide comprises at least 30 percent or at least 50 percent positively or potentially positively charged amino acid residues selected from the group consisting of arginine, lysine, histidine, or mixtures thereof. In certain non-limiting embodiments, the cationic peptide comprises at least 30 percent or at least 50 percent arginine residues (relative to total number of amino acid residues). In certain non-limiting embodiments a cationic peptide according to the invention may comprise, alone or in combination, where the single letter code for amino acids is used:
-
(Homo sapiens; UniProtKB/Swiss-Prot: P04553.2; SEQ ID NO: 1) MARYRCCRSQ SRSRYYRQRQ RSRRRRRRSC QTRRRAMRCC RPRYRPRCRR H; (Homo sapiens; UniProtKB/Swiss-Prot: P04554.3; SEQ ID NO: 2) MVRYRVRSLS ERSHEVYRQQ LHGQEQGHHG QEEQGLSPEH VEVYERTHGQ SHYRRRHCSR RRLHRIHRRQ HRSCRRRKRR SCRHRRRHRR GCRTRKRTCR RH; (Oryzias latipes; NCBI Reference Sequence: NP_001098274.1; SEQ ID NO: 3) MRRQASLPAR RRRRVRRTRV VRRRRRVGRR RH; - PRRRRRSSSR PIRRRRRPRAS RRRRRGGRRR R (chum salmon peak A peptide; SEQ ID NO:4; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990);
- PRRRRSSRRP VRRRRRPRVSR RRRRGGRRRR (chum salmon peak B peptide; SEQ ID NO:5; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990);
- PRRRRSSSRP VRRRRRPRVSR RRRRGGRRRR (chum salmon peak C peptide; SEQ ID NO:6; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990); PRRRRASRRI RRRRRPRVSR RRRRGGRRRR (chum salmon peak D peptide; SEQ ID NO:7; European Medicines Agency, 15 Nov. 2012, EMA/741250/2012, Assessment report for Protamine containing medicinal products, Review under Article 5(3) of Regulation (EC) No 726/2004, citing Hoffman et al., 1990); or
- a peptide comprising the sequence RRRX1 X2 RRR where X1 or X2 or both is/are G or V or A (SEQ ID NO:8).
- In certain non-limiting embodiments, a single species of cationic peptide is used for delivery in the delivery formulation. In certain other non-limiting embodiments of the invention, a mixture of cationic peptides is used. In certain non-limiting embodiments of the invention, a mixture of cationic peptides commercially available as protamine sulfate is used. In a specific non-limiting embodiment the protamine sulfate may be as approved by the United States Food and Drug Administration, for example, as provided in a 10 mg/mL solution by Fresenius Kabi U.S.A. or an equivalent product.
- In certain non-limiting embodiments, the cationic peptide may be linked to another peptide that does not qualify as a cationic peptide and/or to a non-amino acid or non-peptide component, such as, but not limited to, a lipid, a fatty acid, a carbohydrate or a nucleic acid. In certain non-limiting embodiments the cationic peptide may be conjugated to one or more additional molecule, for example, but not limited to, a carbohydrate, an antibiotic, an antiproliferative agent, a pharmaceutical, or another peptide, whose physiochemical properties makes them impermeable across urothelium.
- An “anionic agent” is an agent that may be used as a diagnostic or therapeutic wherein at least a portion of the agent has a negative charge that can form a non-covalent attachment with a cationic peptide. In certain, non-limiting embodiments, the anionic agent is an antisense oligonucleotide. In certain, non-limiting embodiments, the antisense oligonucleotide is at least about 10 nucleic acids long, or at least about 15 nucleic acids long, or at least about 20 nucleic acids long, or at least about 25 nucleic acids long, or up to about 30 nucleic acids long, or up to about 50 nucleic acids long, or up to about 75 nucleic acids long, or up to about 100 nucleic acids long, or between about 15 and 75 nucleic acids long, or between about 15 and 40 nucleic acids long. In certain non-limiting embodiments, the antisense oligonucleotide inhibits the expression/reduces the level of nerve growth factor. In certain non-limiting embodiments, said nerve growth factor is human nerve growth factor encoded by a mRNA having a corresponding cDNA sequence set forth in GenBank Accession No. GenBank: M57399.1, as follows:
-
[SEQ ID NO: 9] 1 tctgctttta ataagcttcc caatcagctc tcgagtgcaa agcgctctcc ctccctcgcc 61 cagccttcgt cctcctggcc cgctcctctc atccctccca ttctccattt cccttccgtt 121 ccctccctgt cagggcgtaa ttgagtcaaa ggcaggatca ggttccccgc cttccagtcc 181 aaaaatcccg ccaagagagc cccagagcag aggaaaatcc aaagtggaga gaggggaaga 241 aagagaccag tgagtcatcc gtccagaagg cggggagagc agcagcggcc caagcaggag 301 ctgcagcgag ccgggtacct ggactcagcg gtagcaacct cgccccttgc aacaaaggca 361 gactgagcgc cagagaggac gtttccaact caaaaatgca ggctcaacag taccagcagc 421 agcgtcgaaa atttgcagct gccttcttgg cattcatttt catactggca gctgtggata 481 ctgctgaagc agggaagaaa gagaaaccag aaaaaaaagt gaagaagtct gactgtggag 541 aatggcagtg gagtgtgtgt gtgcccacca gtggagactg tgggctgggc acacgggagg 601 gcactcggac tggagctgag tgcaagcaaa ccatgaagac ccagagatgt aagatcccct 661 gcaactggaa gaagcaattt ggcgcggagt gcaaatacca gttccaggcc tggggagaat 721 gtgacctgaa cacagccctg aagaccagaa ctggaagtct gaagcgagcc ctgcacaatg 781 ccgaatgcca gaagactgtc accatctcca agccctgtgg caaactgacc aagcccaaac 841 ctcaagcaga atctaagaag aagaaaaagg aaggcaagaa acaggagaag atgctggatt 901 aaaagatgtc acctgtggaa cataaaaagg acatcagcaa acaggatcag ttaactattg 961 catttatatg taccgtaggc tttgtattca aaaattatct atagctaagt acacaataag 1021 caaaaacaa,
and said antisense oligonucleotide is homologous to a portion thereof which is at least about 10 nucleic acids long, or at least about 15 nucleic acids long, or at least about 20 nucleic acids long, or at least about 25 nucleic acids long, or up to about 30 nucleic acids long, or up to about 50 nucleic acids long, or up to about 75 nucleic acids long, or up to about 100 nucleic acids long, or between about 15 and 75 nucleic acids long, or between about 15 and 40 nucleic acids long. As non-limiting examples, analogous antisense oligonucleotides may be directed to mRNAs encoding Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF-β1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/stathmin 1 or PIK-1, inflammatory proteins, cytokines, chemokines, caspase-1, or proteins involved in autophagy such as microtubule-associatedprotein 1 light chain 3 (LC3B), autophagy protein 5 ATGS,beclin 1, LAMP-2, for example but not limited to human Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF-β1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/stathmin 1 or PIK-1, inflammatory proteins, cytokines, chemokines, caspase-1, or proteins involved in autophagy such as microtubule-associatedprotein 1 light chain 3 (LC3B), autophagy protein 5 ATGS,beclin 1, LAMP-2. - In certain, non-limiting embodiments, the anionic agent is an interfering RNA (siRNA) oligonucleotide. In certain, non-limiting embodiments, the siRNA oligonucleotide is at least about 10 nucleic acids long, or at least about 15 nucleic acids long, or at least about 20 nucleic acids long, or at least about 25 nucleic acids long, or up to about 30 nucleic acids long, or up to about 50 nucleic acids long, or up to about 75 nucleic acids long, or up to about 100 nucleic acids long, or between about 15 and 75 nucleic acids long, or between about 15 and 40 nucleic acids long. In certain non-limiting embodiments, the siRNA oligonucleotide inhibits the expression/reduces the level of nerve growth factor. In certain non-limiting embodiments, said nerve growth factor is human nerve growth factor encoded by a mRNA having the corresponding cDNA sequence set forth in GenBank Accession No. GenBank: M57399.1 (for example SEQ ID NO:9 above) and said siRNA oligonucleotide is homologous to a portion thereof which is at least about 10 nucleic acids long, or at least about 15 nucleic acids long, or at least about 20 nucleic acids long, or at least about 25 nucleic acids long, or up to about 30 nucleic acids long, or up to about 50 nucleic acids long, or up to about 75 nucleic acids long, or up to about 100 nucleic acids long, or between about 15 and 75 nucleic acids long, or between about 15 and 40 nucleic acids long. As non-limiting examples, analogous siRNA oligonucleotides may be directed to mRNAs encoding Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF-β1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/
stathmin 1 or PIK-1, inflammatory proteins, cytokines, chemokines, caspase-1, or proteins involved in autophagy such as microtubule-associatedprotein 1 light chain 3 (LC3B), autophagy protein 5 ATGS,beclin 1, LAMP-2, for example but not limited to human Vascular Endothelial Growth Factor (“VEGF”), transforming growth factor-beta1 (“TGF-β1”), Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4/5 (NT-4/5), cell cycle protein involved in cell proliferation and migration such as oncoprotein-18/stathmin 1 or PIK-1, inflammatory proteins, cytokines, chemokines, caspase-1, or proteins involved in autophagy such as microtubule-associatedprotein 1 light chain 3 (LC3B), autophagy protein 5 ATGS,beclin 1, LAMP-2. - Such antisense or siRNA oligonucleotides may comprise non-naturally occurring bases or linkages as are known in the art, for example, but not limited to, phosphorothioate residues, 2′-O-methyl (2′-O-Me) phosphorothioate, 2′-O-methoxyethyl (2′-O-MOE) phosphorothioate residues, Oligodeoxyribonucleotides with phosphonoacetate or thiophosphonoacetate internucleotide linkages, locked nucleic acids, and/or synthethic microRNA, short hairpin RNA, small interfering RNA, piwi-associated RNAs negatively charged homo-oligomers of alternating trans-4-hydroxy-L-proline/phosphonate polyamides (HypNA-pPNA).
- Other anionic compounds that may be used as therapeutic or diagnostic agents include Bacille Calmette-Guerin cell wall skeleton, suramin and (polysulfonated naphtylurea), plasmid DNA, anionic peptides, anionic antifungal peptides.
- In certain non-limiting embodiments, the invention provides for a pharmaceutical composition comprising said cationic peptide(s) and anionic agent(s) for intravesical administration to a subject (a delivery formulation). Said composition may be available as such or may be prepared shortly before administering to the subject by mixing the cationic peptide(s) with the anionic agent(s) or by reconstituting a mixture of the two. In one specific non-limiting embodiment, the cationic peptide mixture is a commercially available protamine injection solution which is mixed with the anionic agent prior to administering to the subject.
- In other non-limiting embodiments, the cationic peptide(s) and the anionic agent are provided as separate components in a kit, to be mixed together to form a delivery formulation shortly before administering to a subject. “Shortly before” means within about 30 days prior to use or within about one week prior to use or within about 3 days prior to use or within about 2 days prior to use or within about 24 hours prior to use or within about 12 hours prior to use or within about 8 hours prior to use.
- In certain non-limiting embodiments, the present invention provides for a mixture that may comprise a therapeutic or diagnostic oligonucleotide in the concentration range of 2-20 micromolar mixed with cationic peptide or cationic peptide mixture (eg protamine sulfate) in the 20-200 micromolar range. In certain non-limiting embodiments, the cationic peptide is protamine and the concentration of protamine is less than 10 mg/mL, or less than 1 mg/mL, or less than 0.6 mg/mL, or less than 0.4 mg/mL, or between 0.2 mg/mL and 0.6 mg/mL, or between about 0.2 mg/mL and 0.4 mg/mL, or about 0.3 mg/mL, or about 0.4 mg/mL.
- In certain non-limiting embodiments, the weight ratio of cationic peptide(s) to anionic agent is between about 1:1 to about 40:1 or between about 5:1 to about 30:1 or between about 5:1 to about 15:1 and/or may be about 1:1 or about 5:1 or about 10:1 or about 15:1 or about 20:1 or about 30:1 or about 40:1.
- In certain non-limiting embodiments, the weight ratio of protamine sulfate to oligonucleotide is between about 1:1 to about 40:1 or between about 5:1 to about 30:1 or between about 5:1 to about 15:1 and/or may be about 1:1 or about 5:1 or about 10:1 or about 15:1 or about 20:1 or about 30:1 or about 40:1.
- The pharmaceutical compositions of the invention may further comprise one or more pharmaceutically suitable solvent, such as but not limited to water and/or saline, and may optionally comprise one or more additional therapeutic or diagnostic agent.
- In certain non-limiting embodiments the present invention provides for a method of treating a subject, in need of such treatment, with an anionic therapeutic agent, comprising administering into the bladder of the subject an effective amount of an anionic therapeutic agent in combination with a cationic peptide(s) in an amount that promotes the uptake of the therapeutic agent into bladder cells. In non-limiting embodiments, the subject may be suffering from overactive bladder (“OAB”), bladder cancer, or interstitial cystitis.
- In certain non-limiting embodiments the present invention provides for a method of performing a diagnostic procedure on the bladder of a subject, comprising administering into the bladder of the subject an effective amount of an anionic diagnostic agent in combination with a cationic peptide(s) in an amount that promotes the uptake of the diagnostic agent into bladder cells, thereby enabling the diagnostic procedure. As a non-limiting example, the diagnostic procedure may be an imaging procedure and the anionic agent may be an imaging dye, whereby the method enhances the ability of the dye to produce an image of the urothelium.
- In certain non-limiting embodiments the present invention provides for a method of treating a subject with overactive bladder, comprising administering into the bladder of the subject a therapeutic amount of an antisense oligonucleotide toward nerve growth factor in combination with a cationic peptide(s) in an amount that promotes the uptake of the antisense oligonucleotide into bladder cells to reduce the level of nerve growth factor and reduce the frequency of urination and/or feeling of urgency to urinate. In a specific non-limiting embodiment the cationic peptide(s) is a mixture of cationic peptides as comprised in a protamine solution.
- A subject may be a human or a non-human subject, including but not limited to a non-human primate, a rodent, a rabbit, a dog, a cat, a horse, a goat, a cow or bull, a sheep, or a bird.
- The present study describes the use of a new carrier for ODN, Protamine, which has been used as a component in the delivery system for gene and ODN in the past, but not in this context [14]. Protamine is highly stable, well characterized and is used clinically as an antidote to heparin overdoses and a complexing agent for insulin in long-acting preparations [15]. It has, however, been reported to have toxic effects when instilled into bladder at relatively higher concentration [21-23].
- A. Methods
- Oligonucleotides: The 18mer phosphorothioated antisense oligonucleotide (ODN) was used in all experiments with the sequence 5′GCCCGAGACGCCTCCCGA (SEQ ID NO: 10), which was directed against unique sequence in exon 3 of rat NGF mRNA and was custom made by Integrated DNA technologies (San Diego, Calif.). ODN had a 5′ tag of TYE™ 563 for uptake studies. Stock solution of HPLC grade ODN was prepared at 2 mM in nuclease free distilled water (Invitrogen, Grand Island, N.Y., USA).
- Protamine: Protamine sulfate Grade X, was purchased from Sigma (Catalog P4020) with a molecular mass of approx. 5.1 KDa and stock solution was prepared at 5 mg/mL. Aliquots of ODN solution containing 5 μg/mL were mixed in mass ratios ranging from 1:1 to 1:40 with aqueous solutions of Protamine sulfate 5-200 μg/mL. The binary complex was incubated at room temperature for 30 minutes prior to experiments and prepared fresh before every experiment.
- Cell lines and cell culture: UROtsa cell line was maintained in a humidified incubator containing 5% CO2-95% atmospheric air at 37° C. in Minimum Essential Medium (Thermo Fisher Scientific, Pittsburgh, Pa.) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) antibiotic/antimycotic (Catalog Number 15240, Invitrogen).
- Intracellular uptake of TYE™-labeled ODN-10,000 cells of UROtsa cell line were plated in an eight-well tissue culture chamber slides made of glass (Falcon, Becton Dickinson, N.Y.) at 37° C. and after 19 h, plated cells were treated with 5 μg/mL of TYE™ 563-labeled ODN or the binary complex containing ODN complexed with protamine 5-200 μg/mL in different mass ratios. All preparations were diluted 2-fold with incomplete media and incubated for 4 hours. After 4 hours, cells were washed to remove residual ODN preparations and then incubated with complete media for 19 h. After incubation, cells were washed three times with cold PBS and were fixed with a 5% (w/w) solution of paraformaldehyde in PBS for 7 min and then embedded in an antifading substance. Images were taken with a fluorescence microscope equipped with a laser (BX51, Olympus America Inc, Center Valley, Pa.,) and image digitized by Magnafire. All optical sections were recorded at the same exposure time and images were processed with the Image software.
- Cell viability: 10,000 cells were seeded in 96-well culture plates and after 19 h, the medium was replaced with incomplete medium containing different concentrations of prepared ODN+protamine complexes for 4 h. The cell media was replaced after ODN exposure with complete culture medium for the next 19 h. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt (5 mg/mL of stock in PBS) was then added (10 μl per well in 100 μl) and plate was further incubated for 5 h. At the end of the incubation period, the reaction mixture was carefully removed and 200 μl of culture grade DMSO was added to each well. The plates were kept on rocker shaker for 10 min at room temperature and then analyzed at 550 nm using multi well micro plate reader (Synergy HT, Bio-Tek, USA). Unexposed sets were also run under identical conditions and served as untreated controls.
- Bladder uptake studies: Rats were anesthetized with 2% isoflurane and their bladders were catheterized by 24-gauge angiocatheters (Becton Dickinson), washed with saline to instill 0.5 mL of fluorescent TYE™ conjugated ODN dissolved in nuclease free water or complexed with protamine for 60 min. Rats restarted their voiding in metabolic cages at the end of instillation. Bladders were harvested at the time of sacrifice and cryopreserved for cryosectioning into 8 micron thick tissue sections. Sections were examined for fluorescence signal by fluorescence microscope equipped with a laser.
- Efficacy studies: 13 rats were anesthetized with 2% isoflurane and 24-gauge angiocatheters were inserted into their urethras. Via these catheters, urine was drained from the bladders and phosphorothioated NGF antisense ODN (2-12 μM) complexed with protamine (n=5), in a volume of 0.5 ml, was instilled. The sham group received saline or protamine sulfate 0.3 mg/mL (n=4) and a control group without any instillation was also included for saline cystometry 24 h after instillation under urethane anesthesia (1.0 g/kg, s.c.). The efficacy of instilled treatments were assessed by comparing results of saline with acetic acid cystometry 0.25% v/v acetic acid in saline infusion at the rate of 0.04 mL/min. A polyethylene catheter (PE-50) was connected by a three-way stopcock to a pressure transducer and to a syringe pump. The catheter was then inserted into the bladder transurethrally for recording intravesical pressure and for infusing solutions into the bladder. The intravesical pressure was recorded with data-acquisition software (
sampling rate 400 Hz; Chart) on a computer system equipped with an analog-to-digital converter. The rats' body temperatures were maintained in the physiologic range using a heating lamp. A control CMG was performed by slowly filling the bladder with saline (0.04 mL/min) to elicit repetitive voiding for more than for 1 hour. Subsequently, bladder irritation was induced by 0.25% AA infusion. The ICI of the reflex bladder contractions during saline and AA was determined as the time between 2 continuing contraction cycles. The average of at least 3 ICIs measured for more than 30 min after saline infusion and 60 min after AA infusion, respectively was compared. - Immunohistochemistry: Following cystometry, bladders were cryopreserved and 8 μm thick cryosections were washed in PBS and pre-incubated with PBS containing 20% normal serum (Jackson Immunoresearch) and 0.2% Triton X-100 (VWR International,) for 2 h at room temperature. The primary polyclonal rabbit H-20 antibody (1:50) (Santa Cruz Biotechnology, Santa Cruz, Calif.) for NGF was applied in PBS containing 5% normal serum, 0.2% Triton X-100 for 16-18 h at 4° C. Sections were washed in PBS containing 0.1% BSA, 0.1% Triton X-100, 4× for 5 min each at room temperature. The secondary donkey anti-rabbit Alexa Fluor 488 (1:200) (Molecular Probes, Eugene, Oreg.) antibody was applied for 2 h at room temperature in PBS containing 0.1% BSA, 0.1% Triton X-100. Washing was performed 3× at room temperature in PBS, and sections were mounted with an aqueous mounting medium. Immunostaining was analyzed with a Nikon confocal microscope.
- NGF levels in harvested bladders: The rat bladders were harvested at the end of cystometry. Tissues were homogenized in RIPA lysis buffer system (Santa Cruz Biotechnology Inc., USA) in the presence of 1 mM Na3VO4, 2 mM PMSF and 10 μL/mL protease inhibitor cocktail. Protein was estimated using pierce BCA protein Assay kit (Thermo Scientific, USA). Tissue lysates were stored at −20° C. until assay and assayed in triplicate in an antigen capture ELISA Emax Immuno-Assay System (Promega, Madison, Wis.) according to the manufacturer's instructions. ELISA plates were read at 450 nm on an Elx800 microplate reader (Bio-Tek Instruments, Winooski, Vt.). Tissue NGF values were normalized against the protein concentrations of each sample and expressed as picograms per milligram of protein.
- B. Results:
- Cellular uptake studies: Cellular uptake was investigated by incubating naked and ODN complexed with protamine at 37° C. for 4 hours and assessing the fluorescent signal in cells 24 h later. Cells treated with ODNs in the absence of protamine showed absence of any fluorescent signal (
FIG. 1A ). In contrast, all protamine/ODN complexes showed protamine concentration dependent increase of ODN uptake. The highest efficacy was found with increasing mass ratios (FIG. 1 &2). At the mass ratio 1:5 the cells seemed to be full of ODN and uptake increased up to 1:10 ratio and cellular toxicity was observed at higher concentration. - Images taken at higher magnification demonstrate that protamine nanoparticles formed with ODN were localized in the nucleus (
FIG. 2G-I ). The binary complex showed toxicity at higher concentration of protamine sulfate inFIG. 1 bottom panel as revealed by decrease in cell viability relative to control untreated cells represented by 0 μg on x-axis. Higher concentration of protamine reduced cell viability. Protamine sulfate induced toxicity is also related to reduced fluorescence (FIGS. 2C & F). Although cellular uptake and subcellular localization of fluorescent ODN is visible at higher magnification (FIG. 2G-I ), images taken at lower magnification showed the uniform uptake of binary complexes and were better in revealing toxicity from higher concentrations of protamine, for example 40 μg per well or 0.2 mg/mL. - Bladder Uptake: Rat bladders harvested after ODN instillation were cryosectioned for viewing the red fluorescence under the microscope (
FIG. 3 ) The fluorescent signal was used as a measure of bladder uptake of ODN after instillation. Protamine mediated bladder uptake of ODN was evident from intense fluorescence of TYE™ 563 in bladder sections. Increasing the dose of TYE™ 563 labeled ODN, while keeping the mass ratio of ODN:protamine 1:10, increased the intensity of fluorescence in bladder. Our previous studies have demonstrated the naked ODN at the concentration of 15 μg/mL (or 0.015 mg/mL) does not transfer into the bladder cells[7]. Fluorescence integrated intensity images are shown below the fluorescent images to reveal the localization of fluorescent signal. - Cystometry: Baseline CMG under saline infusion was indistinct between the groups. Pretreatment of antisense ODN (n=4) complexed with protamine blocked the AA induced bladder overactivity (
FIG. 4A , middle and bottom tracing). The sequence specificity of NGF antisense ODN selected for these experiments has been demonstrated previously, with scrambled ODN sequence not showing any effect [7] in this model. The ICI was longer in the antisense treated group, compared to the sham group and the differences were statistically significant using one-way ANOVA followed by Tukey's post test (*p<0.05) (FIG. 4B ). - Bladder NGF levels: AA exposure elevated the NGF production in the sham group relative to the control group. Pretreatment with NGF antisense ODN significantly blocked the AA induced NGF overexpression in the tissue lysates of bladder (
FIG. 5 ). Results ofFIG. 5 can be directly inferred from the bladder uptake of ODN facilitated by protamine. NGF levels in control rat group not exposed to AA were not raised. - C. Discussion
- A carrier for therapeutic oligonucleotides that is easy to make and instill in the bladder for in vivo experiments as described here has translation potential for patients that are refractory to traditional treatment of overactive bladder (“OAB”), bladder cancer or interstitial cystitis. Protamine is a natural and arginine-rich polycationic peptide of ˜5.1 KDa. It is found in male gametes, where it forms compact structures with DNA and facilitates DNA delivery to the egg nucleus after fertilization. Protamine possesses several amino acid sequences resembling that of a nuclear localization signal[14], which may facilitate DNA delivery to nucleus. It is non-antigenic[16], due to the lack of aromatic amino acids and the lack of a rigid structure[17]. We hypothesized that cationic protamine can self-assemble with the anionic ODN, forming a stable complex, which facilitates the bladder uptake of ODN.
- In earlier experiments protamine was shown to form nanoparticles with ODN [18, 19] in the size range of 100-200 nm. The ratio of bound ODN and number of particles increased with increasing mass ratio of protamine in the binary complex [10]. Binary complexes at mass ratios higher than 1:2 showed positive surface potentials [20] due to excess amounts of cationic peptide. However those observations were only from cell culture and the complexes were yet to be tested in animals, an essential prerequisite for assessing potential clinical benefit.
- The observations described here are unexpected, when considered in the light of the reports describing toxic effects of protamine when instilled into the bladder at relatively higher concentration [21-23]. High concentrations of protamine sulfate (e.g., 10-30 mg/mL) [24] induce damage to the bladder epithelium in animals that mimics the damage to urothelium in interstitial cystitis patients. However, lower concentrations of protamine sulfate were deemed to be safe in the animal experiments as permeability of rat bladder instilled with protamine sulfate at 1 mg/mL [25] was not different from rat bladder instilled with saline. Bladder uptake studies of ODN and efficacy studies shown in
FIG. 3-5 used protamine sulfate the lower concentration of 0.3 mg/mL. - It is known that bladder permeability in the ex vivo setup does not mimic the observation made in the in vivo setup as the former is vulnerable to effects of ischemia and mediators released from excised bladder [26]. This is an important point to consider when interpreting the results from Ussing chamber studies involving excised rabbit bladder, where protamine sulfate at 0.1 mg/mL increased the apical membrane conductance for cations [27, 28]. In fact, results of excised rabbit bladder are consistent with our cell culture experiments, where we found that protamine sulfate at concentrations higher than 0.2 mg/mL was toxic to the UROtsa cells. Taken together, it can be easily inferred that cultured cells and excised bladder cannot mimic the barrier function erected inside the intact bladder of a live animal.
- The optimum mass ratio of 1:10 (ODN:protamine) found from cell culture experiments for complexation of ODN with protamine sulfate was maintained for animal experiments. Following that ratio, 0.3 mg/mL of protamine sulfate was used as a carrier to deliver up to 0.03 mg/mL of ODN to rat bladder. The concentration of 0.3 mg/mL for protamine sulfate is much lower than the concentration of 1 mg/mL found safe in rat [29] and rabbit [25] in vivo experiments. Consistent with earlier reports, we did not observe any toxicity from instilling protamine sulfate at 0.3 mg/mL in absence of ODN in control group. Furthermore, our culture experiments also justify use of 1:5 mass ratio, which permits use of protamine at 0.15 mg/mL, if necessary for future experiments with cystitis rat model with compromised bladder barrier.
- Based on earlier reports, an energy dependent uptake mechanism based on endocytosis is assumed for cellular uptake of protamine+ODN complex [30]. Interaction of cationic peptide with the anionic residues on the cell surfaces seems important for adsorption on cell membranes and internalization. Protamine is considered to facilitate delivery by allowing ODN to escape endocytic vesicles, lysosomal degradation, and its translocation into the nucleus. Present study substantiates the therapeutic potential of the NGF antisense in cell culture and animal experiments.
- Bladder instillation of antisense ODN can be an efficient means to control the expression of therapeutically relevant genes and elucidate the functional role of newly discovered genes in bladder function. Nerve growth factor has emerged as an attractive drug target for OAB [31] and its downregulation with antisense ODN is an potential approach [7]. Recently cationic liposomes have been demonstrated to be effective in intravesical delivery of ODN [7]. However, cationic liposomes will require further modification to curb their cytotoxicity [32] in the event that cystoscope-guided intradetrusor injection into bladder is considered for prolonged duration of action and in treatment of refractory patients. Protamine sulfate in the concentrations of about 0.3 mg/mL used here is less cytotoxic than cationic lipids used in liposomal formulation (7 mg/mL) for intradetrusor injection.
- Various viral and nonviral delivery strategies are being developed for improved gene delivery. However, viral approaches are hindered by side effects such as immunogenicity and toxicity, whereas nonviral delivery systems have limited transfection efficiency and biodegradability issues [33]. Protamine and ODN can be simply mixed together and rapidly delivered, without cumbersome steps attendant to many other types of vectors such as liposomes and polymers or other tools of nanotechnology. The formulation is particularly well suited for localized use, particularly intravesical instillation in the safe dose range for delivery of therapeutic ODN against NGF in treatment of interstitial cystitis, overactive bladder.
- Conclusions: Protamine is an effective carrier for delivering therapeutic ODN to bladder. It non-covalently binds to form a liquid complex for easy instillation into bladder.
-
- 1. Dadgostar, H. and N. Waheed, The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye, 2008. 22(6): p. 761-7.
- 2. Tyagi, P., M. P. Kashyap, N. Kawamorita, T. Yoshizawa, M. Chancellor, and N. Yoshimura, Intravesical Liposome and Antisense Treatment for Detrusor Overactivity and Interstitial Cystitis/Painful Bladder Syndrome. ISRN Pharmacol, 2014. 2014: p. 601653.
- 3. Dadgostar, H. and N. Waheed, The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye (Lond), 2008. 22(6): p. 761-7.
- 4. Gebhard, C., G. Huard, E. A. Kritikou, and J. C. Tardif, Apolipoprotein B Antisense Inhibition—Update on Mipomersen. Curr Pharm Des, 2013. 19(17): p. 3132-42. 5.Blietz, C. E., B. Thode, M. Hauses, R. Pries, A. J. Meyer, C. Doehn, D. Jocham, and I. Kausch, In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer. In Vivo, 2009. 23(1): p. 13-9.
- 6. Martin, T. A. and W. G. Jiang, Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta, 2009. 1788(4): p. 872-91.
- 7. Kashyap, M., N. Kawamorita, V. Tyagi, Y. Sugino, M. Chancellor, N. Yoshimura, and P. Tyagi, Downregulation of NGF Expression in the Bladder by Antisense Oligoucleotides as New Treatment for Overactive Bladder. J Urol, 2013. 190(2):757-64. 8. Nogawa, M., T. Yuasa, S. Kimura, M. Tanaka, J. Kuroda, K. Sato, A. Yokota, H. Segawa, Y. Toda, S. Kageyama, T. Yoshiki, Y. Okada, and T. Maekawa, Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest, 2005. 115(4): p. 978-85.
- 9. Martin, D. T., J. M. Steinbach, J. Liu, S. Shimizu, H. Z. Kaimakliotis, M. A. Wheeler, A. B. Hittelman, W. Mark Saltzman, and R. M. Weiss, Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer. Mol Cancer Ther, 2014. 13(1): p. 71-81.
- 10. Bunnell, B. A., F. K. Askari, and J. M. Wilson, Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet, 1992. 18(6): p. 559-69.
- 11. Tyagi, P., R. Banerjee, S. Basu, N. Yoshimura, M. Chancellor, and L. Huang, Intravesical antisense therapy for cystitis using TAT peptide nucleic acid conjugates. Mol Pharm, 2006. 3(4): p. 398-406.
- 12. Uhlmann, E., A. Ryte, and A. Peyman, Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev, 1997. 7(4): p. 345-50.
- 13. Wojcik, M., M. Cieslak, W. J. Stec, J. W. Goding, and M. Koziolkiewicz, Nucleotide pyrophosphatase/
phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleotides. Oligonucleotides, 2007. 17(1): p. 134-45. - 14. Sorgi, F. L., S. Bhattacharya, and L. Huang, Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther, 1997. 4(9): p. 961-8.
- 15. Hansen, B., S. Linde, K. Kolendorf, and F. Jensen, Absorption of protamine-insulin in diabetic patients. I. Preparation and characterization of protamine-125I-insulin. Horm Metab Res, 1979. 11(2): p. 85-90.
- 16. Rodman, T. C., F. H. Pruslin, Y. Chauhan, S. E. To, and R. Winston, Protamine-reactive natural IgM antibodies in human sera. Characterization of the epitope demonstrates specificity of antigenic recognition; occurrence indicates obscurity of origin and function. J Exp Med, 1988. 167(3): p. 1228-46.
- 17. Tobita, T., M. Nomoto, M. Nakano, and T. Ando, Isolation and characterization of nuclear basic protein (protamine) from boar spermatozoa. Biochim Biophys Acta, 1982. 707(2): p. 252-8.
- 18. Lochmann, D., J. Weyermann, C. Georgens, R. Prassl, and A. Zimmer, Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur J Pharm Biopharm, 2005. 59(3): p. 419-29.
- 19. Lochmann, D., V. Vogel, J. Weyermann, N. Dinauer, H. von Briesen, J. Kreuter, D. Schubert, and A. Zimmer, Physicochemical characterization of protamine-phosphorothioate nanoparticles. J Microencapsul, 2004. 21(6): p. 625-41.
- 20. Junghans, M., J. Kreuter, and A. Zimmer, Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles. Biochim Biophys Acta, 2001. 1544(1-2): p. 177-88.
- 21. Aydin, H., F. Ercan, S. Cetinel, and T. San, Morphological examination of the effects of defibrotide on experimentally induced bladder injury and its relation to interstitial cystitis. Urol Res, 2001. 29(4): p. 263-71.
- 22. Cetinel, S., F. Ercan, S. Sirvanci, O. Sehirli, Y. Ersoy, T. San, and G. Sener, The ameliorating effect of melatonin on protamine sulfate induced bladder injury and its relationship to interstitial cystitis. J Urol, 2003. 169(4): p. 1564-8.
- 23. Chuang, Y. C., M. B. Chancellor, S. Seki, N. Yoshimura, P. Tyagi, L. Huang, J. P. Lavelle, W. C. De Groat, and M. O. Fraser, Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology, 2003. 61(3): p. 664-70.
- 24. Lavelle, J., S. Meyers, R. Ramage, S. Bastacky, D. Doty, G. Apodaca, and M. L. Zeidel, Bladder permeability barrier: recovery from selective injury of surface epithelial cells. Am J Physiol Renal Physiol, 2002. 283(2): p. F242-53.
- 25. Niku, S. D., P. C. Stein, H. C. Scherz, and C. L. Parsons, A new method for cytodestruction of bladder epithelium using protamine sulfate and urea. J Urol, 1994. 152(3): p. 1025-8.
- 26. Li, S., Y. S. Juan, B. A. Kogan, A. Mannikarottu, R. Leggett, C. Schuler, and R. M. Levin, Effects of inosine on response to in vitro hypoxia in absence of substrate on bladder dysfunction in adult rats. Urology, 2009. 73(3): p. 661-4.
- 27. Tzan, C. J., J. R. Berg, and S. A. Lewis, Mammalian urinary bladder permeability is altered by cationic proteins: modulation by divalent cations. Am J Physiol, 1994. 267(4 Pt 1): p. C1013-26.
- 28. Tzan, C. J., J. Berg, and S. A. Lewis, Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol, 1993. 133(3): p. 227-42.
- 29. Shioyama, R., Y. Aoki, H. Ito, Y. Matsuta, K. Nagase, N. Oyama, Y. Miwa, H. Akino, Y. Imamura, and O. Yokoyama, Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. Am J Physiol Regul Integr Comp Physiol, 2008. 295(2): p. R714-8.
- 30. Barthel, F., J. S. Remy, J. P. Loeffler, and J. P. Behr, Gene transfer optimization with lipospermine-coated DNA. DNA Cell Biol, 1993. 12(6): p. 553-60.
- 31. Jacobs, B. L., M. C. Smaldone, V. Tyagi, B. J. Philips, S. V. Jackman, W. W. Leng, and P. Tyagi, Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol, 2010. 17(1): p. 4989-94.
- 32. Nguyen, L. T., K. Atobe, J. M. Barichello, T. Ishida, and H. Kiwada, Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol Pharm Bull, 2007. 30(4): p. 751-7.
- 33. Elsabahy, M., A. Nazarali, and M. Foldvari, Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv, 2011. 8(3): p. 235-44.
- 34. WO 2004087931 A1
- 35. WO 2002010201 A2
- 36. WO 2007069068 A2
- 37. Degols et al., 1989, Nucl. Acids Res. 17(22):9341-9350.
- 38. Hoffmann et al., 1990, Protein Expression and Purification,
Volume 1, p. 127-133. - 39. Kashyap et al., 2013, J. Urol. 190(2):757-764.
- 40. Leonetti et al., 1988, Gene 72: 323-332.
- Various patents and publications are cited herein, the contents of which are hereby incorporated by reference herein in their entireties.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/080,300 US20210052734A1 (en) | 2014-09-05 | 2020-10-26 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462046585P | 2014-09-05 | 2014-09-05 | |
US14/846,536 US10029012B2 (en) | 2014-09-05 | 2015-09-04 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
US16/011,378 US20180333496A1 (en) | 2014-09-05 | 2018-06-18 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
US17/080,300 US20210052734A1 (en) | 2014-09-05 | 2020-10-26 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/011,378 Continuation US20180333496A1 (en) | 2014-09-05 | 2018-06-18 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210052734A1 true US20210052734A1 (en) | 2021-02-25 |
Family
ID=55453739
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/846,536 Active US10029012B2 (en) | 2014-09-05 | 2015-09-04 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
US16/011,378 Abandoned US20180333496A1 (en) | 2014-09-05 | 2018-06-18 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
US17/080,300 Pending US20210052734A1 (en) | 2014-09-05 | 2020-10-26 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/846,536 Active US10029012B2 (en) | 2014-09-05 | 2015-09-04 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
US16/011,378 Abandoned US20180333496A1 (en) | 2014-09-05 | 2018-06-18 | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents |
Country Status (1)
Country | Link |
---|---|
US (3) | US10029012B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024184779A1 (en) * | 2023-03-03 | 2024-09-12 | The University Of British Columbia | Protamine molecules and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
US20220107320A1 (en) | 2019-02-15 | 2022-04-07 | Incelldx, Inc. | Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022806A1 (en) * | 1995-01-25 | 1996-08-01 | Cortrak Medical, Inc. | Delivering an agent to an organ |
US20110274745A1 (en) * | 2009-11-10 | 2011-11-10 | Lipella Pharmaceuticals Inc. | Instillation of liposomal formulation of sirna and antisense oligonucleotides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
EP1305333A4 (en) | 2000-07-31 | 2006-04-12 | Active Motif | Peptide-mediated delivery of molecules into cells |
WO2004087931A1 (en) | 2003-04-03 | 2004-10-14 | Korea Advanced Institute Of Science And Technology | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
AU2006325030B2 (en) | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
WO2008124165A2 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
-
2015
- 2015-09-04 US US14/846,536 patent/US10029012B2/en active Active
-
2018
- 2018-06-18 US US16/011,378 patent/US20180333496A1/en not_active Abandoned
-
2020
- 2020-10-26 US US17/080,300 patent/US20210052734A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022806A1 (en) * | 1995-01-25 | 1996-08-01 | Cortrak Medical, Inc. | Delivering an agent to an organ |
US20110274745A1 (en) * | 2009-11-10 | 2011-11-10 | Lipella Pharmaceuticals Inc. | Instillation of liposomal formulation of sirna and antisense oligonucleotides |
Non-Patent Citations (4)
Title |
---|
Dinauer et al. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. Journal of Controlled Release. 2004; 96: 497– 507. (Year: 2004) * |
GenBank: M57399.1 Human nerve growth factor (HBNF-1) mRNA, complete eds. https://www.ncbi.nlm.nih.gov/nuccore/M57399.1 downloaded 9/17/2022. (Year: 2022) * |
Lee et al. The nucleotide sequence of a human protamine 1 cDNA. Nucleic Acids Res. 1987 Sep 25; 15(18):7639. (Year: 1987) * |
Yeh et al. Light-Scattering Investigation of Protamine Sulfate. Journal ofPharmaceutica1 Sciences. 1969; 58(9): 1163-1164. (Year: 1969) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024184779A1 (en) * | 2023-03-03 | 2024-09-12 | The University Of British Columbia | Protamine molecules and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US10029012B2 (en) | 2018-07-24 |
US20160074521A1 (en) | 2016-03-17 |
US20180333496A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210052734A1 (en) | Peptide-mediated intravesical delivery of therapeutic and diagnostic agents | |
AU2019210578B2 (en) | C/EBP alpha saRNA compositions and methods of use | |
JP6621409B2 (en) | C / EBPα small molecule activated RNA composition | |
KR101585947B1 (en) | Targeting agent for cancer cell or cancerassociated fibroblast | |
Kim et al. | Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain | |
US20180258429A1 (en) | Sarna compositions and methods of use | |
US11965163B2 (en) | HNF4a saRNA compositions and methods of use | |
JP6141517B2 (en) | Adipocyte-targeted non-viral gene carrier | |
TW201000134A (en) | Therapeutic agent for fibroid lung | |
JP2008526749A (en) | Sustained release delivery of PDGF using self-assembling peptide nanofibers | |
US20240018519A1 (en) | Stabilized saRNA Compositions and Methods of Use | |
Sun et al. | An Antisense Oligonucleotide-Loaded Blood–Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson’s Disease | |
CN110384801B (en) | Application of miRNA552 cluster microRNA in treatment of LDLC related metabolic diseases | |
US20240002850A1 (en) | SIRT1-saRNA Compositions and Methods of Use | |
WO2023099884A1 (en) | Pax6 sarna compositions and methods of use | |
US20150297686A1 (en) | Tissue regeneration promoting agent | |
US20220211740A1 (en) | Sirt1-sarna compositions and methods of use | |
Yang et al. | Repairing the retinal ischemic microenvironment with an engineered exosome-loaded dehydroepiandrosterone peptide hydrogel | |
WO2024201471A1 (en) | Oca2 modulators, compositions and uses thereof | |
KR20230160872A (en) | TMEM173 SARNA composition and methods of use | |
WO2024165876A2 (en) | Compositions and methods of using c/ebp alpha sarna | |
Naveilhan et al. | Enteric glia inhibit intestinal epithelial cell proliferation | |
WO2009153418A1 (en) | Harp peptides inhibiting tumour growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |